Compare FVRR & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FVRR | SLDB |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 533.3M | 498.6M |
| IPO Year | 2019 | 2017 |
| Metric | FVRR | SLDB |
|---|---|---|
| Price | $10.46 | $7.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $18.43 | $15.00 |
| AVG Volume (30 Days) | ★ 1.7M | 1.5M |
| Earning Date | 01-01-0001 | 06-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,094,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.83 | N/A |
| P/E Ratio | $22.05 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.15 | $2.45 |
| 52 Week High | $34.13 | $8.47 |
| Indicator | FVRR | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 31.41 | 58.84 |
| Support Level | $10.25 | $5.16 |
| Resistance Level | $17.34 | N/A |
| Average True Range (ATR) | 0.51 | 0.58 |
| MACD | 0.16 | 0.13 |
| Stochastic Oscillator | 18.60 | 67.08 |
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Wiring and Translation, and Video and Animation among others.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.